Trilaciclib May Reduce Hospitalization and Improve Survival

Patients with extensive-stage small cell lung cancer (ES-SCLC) who receive trilaciclib appear to experience lower rates of hematologic adverse effects than those who are not treated with the agent.

Related Keywords

Boston , Massachusetts , United States , Tennessee , American , Raj Malik , Therapeutics Inc , American Society Of Clinical Oncology , Cancer Network , American Society , Clinical Oncology Quality Care , Clinical Oncology , Quality Care , Quality Care Symposium , Lung Cancer , Outcomes , Hospitalization , Trilaciclib ,